The SARS-CoV-2 Omicron BA.1 sublineage has been replaced in numerous nations by the BA.2 sublineage. BA.2 contrasts with BA.1 by around 21 changes in its spike. Here, we originally analyzed the responsiveness of BA.1 and BA.2 to balance by 9 remedial monoclonal antibodies (mAbs). As opposed to BA.1, BA.2 was delicate to Cilgavimab, incompletely restrained by Imdevimab, and impervious to Adintrevimab and Sotrov. We then examined sera from 29 immunocompromised people as long as one month after the organization of the Ronapreve (Casirivimab and Imdevimab) and additionally Evusheld (Cilgavimab and Tixagevimab) neutralizer mixed drinks. All treated people showed raised counteracting agent levels in their serum, which proficiently killed the Delta variation. Sera from Ronapreve beneficiaries didn’t kill BA.1 and feebly repressed BA.2. Balance of BA.1 and BA.2 was recognized in 19 and 29 out of 29 Evusheld beneficiaries, individually. When contrasted with the Delta variation, killing titers were all the more extraordinarily diminished against BA.1 (344-overlap) than BA.2 (9-crease). We further report 4 advancement Omicron diseases among the 29 people, showing that counter-acting agent treatment didn’t completely forestall contamination. All things considered, BA.1 and BA.2 show observable contrasts in their aversion to restorative mAbs. Hostile to Omicron killing movement of Ronapreve, and less significantly that of Evusheld, is decreased in patients’ sera.